Interleukin-3 Does Not Affect the Differentiation of Mast Cells Derived from Human Bone Marrow Progenitors by Shimizu, Yuji et al.
Immunological Investigations, 37:1–17, 2008
Copyright © Informa Healthcare USA, Inc.
ISSN: 0882-0139 print / 1532-4311 online
DOI: 10.1080/08820130701741742
LIMM 0882-0139 1532-4311 Immunological Investigations, Vol. 37, No. 1, November 2008: pp. 1–26 Immunological Investigations
Interleukin-3 Does Not 
Affect the Differentiation 
of Mast Cells Derived 
from Human Bone 
Marrow Progenitors
Effect of IL-3 on Mast Cell Differentiation Y. Shimizu et al.
Yuji Shimizu,1,2 Kenji Matsumoto,3 Yoshimichi Okayama,3 
Kentaro Sakai,4 Toshitaka Maeno,2 Tatsuo Suga,2 Toru Miura,5 
Shinji Takai,6 Masahiko Kurabayashi,2 and Hirohisa Saito3
1Department of Respiratory Medicine, National Hospital Organization, Takasaki
Hospital, Takasaki, Japan
2Department of Medicine and Biological Science, Gunma University Graduate School
of Medicine, Maebashi, Japan
3RIKEN Research Center for Allergy and Immunology, Yokohama, Japan
4Department of Nutrition and Health Promotion, Faculty of Human Life Science,
Hiroshima Jogakuin University, Hiroshima, Japan
5Kirin Brewery Incorp., Takasaki, Japan
6Department of Pharmacology, Osaka Medical College, Osaka, Japan
Although IL-3 is commonly used for culture of human progenitor-derived mast cells
together with Stem cell factor (SCF) and IL-6, the effect of IL-3 on human mast cell
differentiation has not been well elucidated. Human bone marrow CD34+ progeni-
tors were cultured for up to 12 weeks in the presence of rhSCF and rhIL-6 either
with rhIL-3 (IL-3 (+)) or without rhIL-3 (IL-3 (−)) for the initial 1-week of culture.
Total cell number increased at 2 weeks in IL-3 (+), as compared to IL-3 (−), but
changes in the appearance of mast cells were delayed. When IL-3 was present for
the initial 1-week culture, granules looked more mature with IL-3 than without
IL-3. However, tryptase and chymase contents, and surface antigen expression
(CD18, CD51, CD54, and CD117) were not altered by IL-3. Surface expression and
mRNA level of FcεRIα and histamine release by crosslinking of FcεRIα did not differ
from one preparation to the next. GeneChip analysis revealed that no significant
differences were observed between IL-3 (+) and IL-3 (−) cells either when inactivated
or activated by aggregation of FcεRIα. These findings indicate that initial
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incubation of human bone marrow CD34+ progenitors with IL-3 does not affect the
differentiation of mast cells.
Keywords Interleukin-3, Human mast cells, Bone marrow, Stem cell factor,
Differentiation.
INTRODUCTION
IL-3 plays an important role in the growth, survival and differentiation of
eosinophils (Gregory, 2003) and basophils (Zheng, 2002). In rodent models,
stimulation of progenitors with IL-3 acting in synergy with SCF has been
required for the development of mast cells. Through experiments with IL-3-
deficient mice, however, IL-3 has been shown not to be essential for the gener-
ation of mast cells, but to contribute to increased numbers of tissue mast cells,
enhanced basophil production, and protective immunity against parasites, as
evidenced in mice with and without a deletion of the IL-3 gene that were
infected with Strongyloides venezuelensis (Lantz, 1998).
In humans, exogenous SCF is essential for the differentiation and activation
of mast cells. IL-6 was shown to be effective in stimulating the proliferation of
differentiated mast cells derived from human cord blood progenitors (Saito,
1996). However, it is controversial whether IL-3 affects the differentiation of
mast cells in humans. Kirshenbaum et al. have found that IL-3 alone and in
combination with SCF promoted the growth and survival of human mast cells
from bone marrow progenitors (Kirshenbaum, 1992, Kirshenbaum, Kessler, Goff
and Metcalfe, 1991). Yanagida et al. (1995) reported that functions in cultured
cord blood mast cells could be regulated by IL-3 and its receptor. Conditioned
medium from a cell line derived from a patient with mastocytosis was shown to
induce the generation of mast cells that possess high affinity IgE receptors from
unsorted bone marrow cells (Li, 1995), although most cells developed into mast
cells that lack tryptase (Li, Meng and Krilis, 1996).
We have established a human mast cell culture system from CD34+ bone
marrow progenitors. When CD34+ progenitors are cultured in the presence of
rhSCF + rhIL-6, predominant cells develop into tryptase- and chymase-posi-
tive human bone marrow mast cells (HBMMC) (Shimizu, 2002). Functional
FcεRIα was constitutively expressed, and its expression preceded that of
tryptase during differentiation (Shimizu, 2004).
It was shown that a combination of 3 signals through gp130, c-kit and IL-3R
exerted a dramatic synergistic effect on hematopoietic colony formation (Kimura,
1997). It is recommended that IL-3 at lower concentration be added only at the
beginning of the culture in the human cord blood system to obtain highly purified
mast cells (Saito, 2006). However, morphological, functional and molecular differ-
ences have not been well elucidated when progenitors were cultured with IL-3.
We therefore investigated whether IL-3 affects the differentiation of HBMMC.Effect of IL-3 on Mast Cell Differentiation 3
MATERIALS AND METHODS
Chemicals
Peroxidase-conjugated streptavidin (Biosource International, Camarillo,
CA), N, N-dimethylformamide (Aldrich Chemical Company Inc., Milwaukee,
WI), naphthol AS-MX phosphate, L-glutamine, levamisole, collagenase, and
the AEC chromogen kit (Sigma, St Louis, MO); human serum AB (Cosmo Bio
CO., LTD, Tokyo, Japan); and Ficoll-Paque research grade (Pharmacia
Biotech AB, Uppsala, Sweden), were purchased commercially. Media III,
which contains insulin (10 μg/ml), transferrin (10 μg/ml), HEPES (4,470 μg/
ml), NaHCO3 (2.3 mg/ml), penicillin (100 U/ml), and streptomycin (100 μg/ml),
was purchased from Immuno-Biological Laboratories, Fujioka, Japan. RhSCF
was a gift from AMGEN Inc. (Thousand Oaks, CA). RhIL-3 and rhIL-6 were
from Kirin Brewery Inc (Takasaki, Japan).
Antibodies
Anti-tryptase mAb conjugated to alkaline phosphatase (G3/AP) was
kindly provided by Professor Lawrence B. Schwartz (Virginia Commonwealth
University, Richmond, VA). CRA-1, used for the detection of FcεRIα by either
immunocytochemistry or flow cytometric analysis (Ra, 1993; Yanagihara,
1994), was purchased from Kyokuto Pharmaceutical Indust. Co. Ltd (Ibaraki,
Japan). For flow cytometry, cells were incubated with several monoclonal
antibodies (mAbs) recognizing various CD antigens. Most of them were
obtained from the 6th International Workshop and Conference on Human
Leukocyte Differentiation Antigens (Kishimoto, 1997).
Anti-human CD117 mAb (YB5.B8)(Pharmingen, San Diego, CA), anti-CD123
mAb (IL-3R, 6H6)(Serotec, Kidlington, Oxford, UK), MOPC 31C (irrelevant
mouse IgG1 control), and MOPC 141 (irrelevant mouse IgG2b control) (Sigma
Chemical CO., St Louis, MO), were purchased commercially. Purified human
IgE and goat anti-human IgE polyclonal antibody were obtained from
Chemicon (Temecula, CA).
Cell Culture
Human bone marrow was collected in a heparinized tube from patients
without any hematological disorders with informed consent. The protocol was
approved at the Institutional Review Board of Gunma University. Bone
marrow CD34+ cells were magnetically sorted with a CD34 progenitor isola-
tion kit (Miltenyi Biotec, Bergisch Gladbach, Germany), as described previ-
ously (Shimizu, 2002). Sorted cells were washed, resuspended in Media III
supplemented with 10% human serum AB, 2mM L-glutamine and 50 μmol/L
2-mercaptoethanol, and seeded into plastic 48-well plates (Iwaki Glass, Tokyo,4 Y. Shimizu et al.
Japan) at a concentration of 5 × 104 cells/ml with a final concentration of 100
ng/ml rhSCF and 50 ng/ml rhIL-6.
Half of the CD34+ cells were cultured in the presence of rhIL-3 (final
concentration, 10 ng/ml). Cells were cultured in 5% CO2 at 37°C in a humid-
ified atmosphere. Half of the medium was exchanged once a week with the
same concentration of rhSCF and rhIL-6 (no IL-3 added). A small propor-
tion of suspended cells were stained with modified toluidine blue as
described by Kimura et al. (Kimura, Moritani and Tanizaki, 1973), and cells
stained metachromatically were counted by haemacytometer at each time
point.
Electron Microscopy
HBMMC at 12 weeks of culture in the presence of rhSCF+rhIL-6 either
with or without IL-3 for the first week of culture were spun down at 250 × g for
8 minutes. Cell pellets were then fixed in 2.5% glutaraldehyde in 0.1% cacody-
late buffer, pH 7.4, for 1 hr at 4°C. The specimens were then washed with the
same buffer, and postfixed with 1% osmium tetroxide for 1 hr. The samples
were dehydrated in a graded ethanol series and embedded in Epon. Thin
sections were cut with an ultramicrotome, and stained with a saturated
aqueous solution of uranyl acetate and lead citrate, and observed with a
JEM-1200EXII (JEOL. Ltd., Tokyo, Japan).
Measurement of Mediators and Mediator Release Assay
Different forms of tryptase (both total and β-tryptase) in HBMMC were
measured using the sandwich ELISA, as described previously (Schwartz,
1994). Chymase was also measured by sandwich ELISA, as described (Takai,
et al., 2000), using anti-chymase mAb (developed by the Department of
Pharmacology, Osaka Medical College, Osaka, Japan) as a capture antibody,
and biotinylated anti-chymase mAb (Chemicon International, London, UK) as
a detection antibody.
For the quantification of histamine, HBMMC (93–99% mast cells) were
sensitized overnight with or without 2 μg/ml of purified human IgE in the
presence or absence of 100 ng/ ml rhSCF at 37°C. Cells were transferred into
centrifuge tubes, washed with Media III, and then challenged with or without
2 μg/ml goat anti-human IgE in the presence or absence of 100 ng/ ml rhSCF
for 30 min at 37°C. After challenge, cells were immediately spun down at 4°C,
and supernatants were collected. After the removal of supernatants, cell
pellets were resuspended in serum free-Media III, and lysed. The amount of
histamine in supernatants and cell pellets was then quantified by radioimmu-
noassay with Histamine Kit (Immunotech S.A., Cedex, France), as recom-
mended by the manufacturer. Percent histamine release was calculated as
follows:Effect of IL-3 on Mast Cell Differentiation 5
Real-Time Quantitative RT-PCR
Total RNA was isolated from either CD34-sorted cells, or mast cell/
mast cell precursors at 2-, 4-, and 12-weeks of culture with an RNeasy mini
kit according to the manufacturer’s instructions (Qiagen Inc., Valencia,
CA). Forward and reverse oligonucleotide primers were constructed with
Primer Express software (Applied Biosystems, Foster City, CA), and
purified by Invitrogen Life Technologies (Tokyo, Japan). The primers were
as follows: tryptase 5′-CAGTGGGTGCTGACCGC-3′ (nucleotide position
251), and reverse 5′-GCAGTTGCACCCTGAGGG-3′ (position 323); FcεRIα
forward 5′-GCCTTACTGTTCTTCGCTCCAG-3′ (position 146), and reverse
5′-CCATGGAGGGTTCAAGGAGAC-3′ (position 220); GAPDH forward
5′-CTTCACCACCATGGAGAAGGC-3′, and reverse 5′-GGCATGGACTGTG
GTCATGAG-3′. TaqMan probes for use in real time RT-PCR were also
designed with Primer Express software, and prepared by Applied
Biosystems.
The probe sequences for tryptase, FcεRIα, and GAPDH, respectively,
were: 5′-CGGACGTCAAGGAT-3′ (position 285), 5′-TGGCGTGTTAGCAGTC
CCTCAGAAACC-3′ (position 169), and 5′-CCTGGCCAAGGTCATCCATGA
CAACTTT-3′. Real time RT-PCR was performed with an ABI PRISM( 7700
Sequence Detection System (Applied Biosystems Japan Ltd., Tokyo, Japan),
as described previously (Shimizu, 2004).
GeneChip Expression Analysis
HBMMC (0.5–2 × 106 cells) cultured in the presence or absence of IL-3
were activated by IgE crosslinking, as shown below, and total RNA (0.5–2 μg)
was extracted from inactivated or activated cells. Human genome-wide gene
expression was examined using the Human Genome U133A probe array
(GeneChip, Affymetrix, Santa Clara, CA), according to the manufacturer’s
protocols (Affymetrix, Inc., Santa Clara, CA) as described previously
(Nakajima, 2001; Okumura, 2003). Data were considered significant when the
level of expression changed by at least 3-fold.
Flow Cytometry and Cell Sorting
HBMMC at 12 weeks of culture in the presence or absence of IL-3 for the
initial week of culture were washed with PBS/ 1% BSA (94 to 99% of cells
exhibited metachromasia and were labeled with G3/AP). Cells were then
% histamine release =
histamine in supernatants
histamine in   cell pellets + supernatants6 Y. Shimizu et al.
incubated with several mAbs or irrevalent isotype-matched control IgG1 or
IgG2b for 30min at 4°C. Cells were washed three times with PBS/ BSA, and
incubated with a FITC-conjugated F(ab’)2 fragment of rabbit anti-mouse
immunoglobulins for 30 min at 4°C.
After 3 washes with PBS/BSA, cells were resuspended in sheath fluid, and
subjected to flow cytometry. Propidium iodide was added (at a final concentra-
tion of 10 μg/ml) prior to the analysis to exclude dead cells, and fluorescence
was analyzed with an EPICS ELITE Flow Cytometer (Coulter, Hialeah, FL).
The analysis was performed with at least 5,000 cells using WinMDI software
(Coulter).
Statistics
Statistical analyses were made with Student’s t-test. Results were
expressed as means plus or minus standard errors of the means unless
otherwise indicated.
RESULTS
1. Differentiation of human bone marrow CD34+ cells in the presence of
SCF+IL-6 either with or without the initial stimulation with IL-3.
CD34-sorted cells obtained from human bone marrow were cultured
with or without an initial 1 week stimulation with IL-3 in the presence
of rhSCF+rhIL-6 for up to 12 weeks, and total cell number and the
percentage of metachromatic cells were determined by staining with
toluidine blue. Cells cultured with IL-3 for the first week were desig-
nated as ‘IL-3 (+) cells’. Cells cultured without IL-3 were termed “IL-3
(−) cells.” The constant incubation with IL-3 during culture induced the
differentiation of CD34+ cells into non-mast cells such as eosinophils
and basophils (data not shown). As shown in Figure 1A, 1 × 105 CD34+
progenitor cells increased 17.4 ± 4.5 times at 2 weeks of culture in IL-3
(+) cells, and 6.1 ± 2.8 times in IL-3 (−) cells. After 4 weeks of culture,
the number of cells was not significantly different between these
groups.
In spite of the temporal increase in the number of IL-3 (+) cells, 3 ± 0.8%
showed metachromasia at 4 weeks of culture, whereas 24 ± 14% of IL-3 (−)
cells showed metachromasia, as shown in Figure 1B. The % metachro-
matic cells increased along with mast cell differentiation, and maximal
ratio of toluidine blue-positive cells reached more than 95% in both prepa-
rations. Cytospin preparations were also stained immunocytochemically
with G3/AP, which showed similar data as toluidine blue stain (data not
shown).Effect of IL-3 on Mast Cell Differentiation 7
2. Ultrastructural appearance of HBMMC (IL-3 (+) or (−)) examined by elec-
tron microscope.
IL-3 (+) and IL-3 (−) cells were subjected to electron microscopy. As
shown in Figures 2A and 2B, each IL-3 (−) cell had a large and irregular
nucleus with condensed chromatin. Almost every granule contains an
electron dense core, with most of the granule remaining electron lucent,
as reported previously (Shimizu, 2002). IL-3 (+) cells had a similar shaped
nucleus, but the granules were filled with electron lucent materials, as
shown in Figures 2C and 2D. The density of the granules in IL-3 (+) cells
was lower than that in IL-3 (−) cells, and compact solid-core scrolls were
partially detected, which have been shown to be present in both MCT and
MCTC (Craig et al., 1988). We therefore quantified tryptase and chymase
in each cell preparation.
Figure 1: Effect of IL-3 on the differentiation of human bone marrow CD34 progenitors into
mast cells. CD34+ human bone marrow progenitors were cultured with () or without () IL-3
for the initial 1 week in the presence of rhSCF+rhIL-6. Total cell number (A) and the percent-
age of metachromatic cells (B) was determined with toluidine blue stain for up to 12 weeks.
Data are expressed as the mean ± SEM of five independent experiments.
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3. Quantification of granule enzymes stored in IL-3 (+) and IL-3 (−) cells at
12 weeks of culture.
Both tryptase and chymase in mast cell granules were quantified by
ELISA. As shown in Figure 3, chymase in 12-week-old IL-3 (+) cells (9.71
± 1.45 pg/ cell) and IL-3 (−) cells (7.25 ± 0.77 pg/ cell) was not significantly
different between IL-3 (+) and IL-3 (−) cells. Tryptase (both total and β) in
IL-3 (+) (8.27 ± 3.94 and 7.34 ± 3.60 pg/ cell, respectively) and IL-3 (−)
(13.65 ± 8.75 and 13.49 ± 9.36 pg/ cell, respectively) were also not signifi-
cantly different in the two preparations.
Figure 2: Electron microscopic appearance of 12-week-old HBMMC in the presence or
absence of IL-3 for the initial 1 week of culture. Ultrastructural analysis of HBMMC cultured in
the presence of rhSCF + rhIL-6 either with (A, B) or without (C, D) IL-3. Note that granules were
filled with materials when IL-3 was added for the initial 1 week of culture. Representative elec-
tron micrographs are shown. Original magnification of Fig 2A and 2C is ×2,000, and Fig 2B and
2D is ×10,000.
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4. Quantitative mRNA levels during differentiation.
Percent tryptase RNA divided by GAPDH RNA in IL-3 (+) and IL-3 (−)
cells (% value of mean mRNA levels as compared to 12-week-old
HBMMC is also shown) was 1.3 ± 0.5 (0.07%) and 1.6 ± 0.8 (0.11%) at 0
week, 2.1 ± 0.8 (0.12%) and 5.3 ± 2.0 (0.36%) at 2 weeks, 24.7 ± 20.7
(13.9%) and 302.7 ± 141.6 (20.6%) at 4 weeks, and 1773.1 ± 574.7 and
1470.1 ± 421.8 at 12 weeks, respectively, as shown in Figure 4A. Percent
FcεRIα RNA divided by GAPDH RNA in IL-3 (+) and IL-3 (−) cells was
1.9 ± 1.5 (2.4%) and 1.9 ± 1.5 (4.0%) at 0 week, 8.9 ± 7.5 (11.2%) and 2.0 ±
1.2 (4.2%) at 2 weeks, 43.1 ± 21 (54.4%) and 20.0 ± 9.8 (41.8%) at 4
weeks, and 79.3 ± 47.3 and 47.9 ± 23.9 at 12 weeks, respectively, as
shown in Figure 4B. The transition of chymase transcript was similar to
that of tryptase transcript (data not shown). Tryptase transcript level
was reduced when progenitors were incubated initially with IL-3, but
FcεRIα transcript was not significantly different between IL-3 (+) and
IL-3 (−) cells. At 12 weeks, the transcript of tryptase and FcεRIα reached
a similar level.
5. Surface expression of FcεRIα, CD13, CD123 and integrins on HBMMC
cultured initially either with or without IL-3.
As reported previously, HBMMC cultured in the presence of rhSCF +
rhIL-6 constitutively express FcεRIα on the cell surface, but CD123
Figure 3: Quantification of tryptase (both total and β) and chymase in IL-3 (+) and IL-3 (−) cells
cultured for 12 weeks in the presence of rhSCF + rhIL-6. IL-3 (+) and IL-3 (−) cells were col-
lected, and pellets were sonicated. Tryptase (both total and β) and chymase were measured
by ELISA. Data are the mean ± SEM of three independent experiments.
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(IL-3 receptor) was undetectable (Shimizu, 2002). We therefore com-
pared the expression of these molecules on HBMMC. IL-3 did not alter the
expression of FcεRIα and CD123, as shown in Figure 5. The expression of
integrins such as CD18, CD51 and CD54 were examined, but there were
no significant differences between IL-3 (+) and IL-3 (−) cells.
6. Histamine release from HBMMC by crosslink of FcεRIα in the presence or
absence of rhSCF.
We next evaluated the histamine release from HBMMC. As shown in
Figure 6A, spontaneous histamine release (without IgE crosslink) from
IL-3 (+) cells was 10.2 ± 1.5%, and 15.6 ± 1.0% from IL-3 (−) cells. When
rhSCF was present, 12.1 ± 3.5% of spontaneous histamine release was
Figure 4: Quantitative mRNA level of tryptase and FcεRIα during differentiation. Total RNA was
extracted from CD34 progenitors, and mast cell/ mast cell progenitors either with or without
IL-3 at 2, 4, and 12 weeks of culture. Real time RT-PCR was then performed to show the transi-
tion of the transcript of tryptase and FcεRIα. Data are the mean ± SEM of 3 independent
experiments.
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Figure 5: Consistent surface expression of FcεRIα, CD123 and integrins on HBMMC cultured ini-
tially either with or without IL-3. HBMMC (either IL-3(+) or IL-3(−)) were labeled with specific mAb
against FcεRIα, CD123, CD117 and integrins such as CD18, CD51, and CD54, or subtype-
matched irrevalent mouse IgG (shaded area) subsequently labeled with FITC-conjugated rab-
bit anti-mouse immunoglobulins. Fluorescence intensity was analyzed by flow cytometry.
Histograms with specific mAb were overlaid with those using the isotype-matched mouse IgG.
Data are representative of three independent experiments that showed similar results.
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observed from IL-3 (+), and 22.5 ± 3.4% from IL-3 (−), as shown in Figure 6B.
Histamine release by IgE crosslink was dose dependently increased in
both IL-3 (+) and IL-3 (−) cells, but there was no significant difference
between the groups. Why spontaneous release of histamine from IL-3 (−)
cells is higher than that from IL-3 (+) cells remains to be determined.
7. Comprehensive analysis of IL-3-regulated and IgE-challenged gene
expression by HBMMC.
To identify genes regulated by IL-3 and aggregation of FcεRI, Gene-
Chip analysis was performed. Each signal (average difference) was nor-
malized with the median value of each GeneChip. Approximately 23,000
transcripts were analyzed, and 1,994 transcripts were subjected to
Figure 6: Histamine release by crosslink of FcεRIα. HBMMC (either IL-3 (+) or IL-3 (−)) were sensi-
tized overnight at 37°C with IgE (2 μg/ml) then challenged with anti-IgE (2 μg/ml) for 30 min at
37°C in the absence (A) or presence of 100 ng/ml rhSCF (B). Cells were centrifuged, and then
supernatants were collected. Histamine levels in sonicated cells and supernatants were mea-
sured and % histamine release was calculated as described in Materials and Methods. Data
are the mean ± SEM of 3 independent experiments.
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clustering analysis after eliminating the transcripts having low levels
(less than 3-fold of the median signal) or absent calls. The transcripts
were further screened based on the three-fold increase in inactivated or
activated with IgE crosslinking between IL-3 (+) and IL-3 (−) cells.
Finally, we found 3 and 19 transcripts that were up-regulated or down-
regulated in inactivated IL-3 (+) cells, respectively. The 95 and 3 tran-
scripts, respectively, were found to be up-regulated or down-regulated
by IgE crosslinking in both IL-3 (+) and IL-3 (−) cells. However, 1 and 2
transcripts, respectively, were up- or down-regulated by IgE crosslink in
IL-3 (+) cells as compared to IL-3 (−) cells. 0 and 1 transcript, respec-
tively, were up- or down-regulated by IgE crosslinking in IL-3 (−) cells.
There was no mast cell-specific transcript between the cells cultured in
the presence or absence of IL-3 and activated/ inactivated with IgE
crosslinking.
DISCUSSION
IL-3 is an important growth and differentiation factor for eosinophils and
basophils. IL-3 is also an essential growth and differentiation factor for mouse
mast cell development in vitro (Thompson et al., 1990; Wright, 2006). In
contrast, in vivo, IL-3 is dispensable for mouse mast cell development, but is
required for normal mast cell expansion during immune responses to
parasites (Lantz, 1998).
SCF and IL-3 induce signal transduction through several pathways
including phospholipase C, Ras-MAP kinase, and Stat5 (Shelburne, 2003) in
mouse mast cell development. Of these proteins, Stat5 is important, since it is
activated by both SCF and IL-3 (Shelburne, 2002). The absence of Stat5
resulted in a total loss of in vivo mast cell development.
In humans, IL-3 is thought to have little effect, if any, on mast cell differ-
entiation (Schwartz, 2002). Recently, IL-3 was used for the culture of human
CD34+ cells derived from cord blood, and it is controversial whether IL-3
affects the differentiation of human mast cells. There are two time points for
the addition of IL-3 in the culture system. Nakajima et al. added IL-3 to the
culture media of mast cells after 11 weeks of culture to prevent apoptosis
(Nakajima, 2002). Yanagida et al. found IL-3R on human cord blood-derived
cultured mast cells, but it had a negligible effect on IgE/ anti-IgE antibody-
induced histamine release (Yanagida, 1995).
The other time point for the addition of IL-3 was considered based on the
report by Kirshenbaum et al. They added IL-3 to CD34+ cells at the early
stage of differentiation, which is commonly recommended for mast cell culture
(Saito, 2006). It has also been reported that IL-3 at low concentration can
enhance the growth of mast cell colonies without inducing granulocyte or
macrophage (GM) colonies in cord blood-derived mast cells (Okayama and14 Y. Shimizu et al.
Kawakami, 2006). However, whether early stimulation of progenitors with
IL-3 affects the differentiation of mast cells has not been well elucidated.
In the experiments shown here, a low concentration of rhIL-3 was added at
an early stage to investigate the effect of IL-3 at the precursor level. As shown
in Figure 1, total cell number temporarily increased and the appearance of
metachromatic cells was reduced when IL-3 was present at the early phase of
differentiation, but the final cell number was not significantly different
between IL-3 (+) and IL-3 (−) cells. Encabo et al reported that IL-3 was benefi-
cial in the expansion of total cells, CD34+ cells, CD133+ cells, and colony form-
ing units (CFU), but detrimental to the increase of telomerase activity and to
the number of long-term culture-initiating cells (LTC-IC) which are the more
immature hematopoietic precursors (Encabo, Mateu, Carbonell-Uberos and
Minana, 2003). Our data also suggest that the precursor cells increased proba-
bly because of the temporal increase in telomerase activity, and that differenti-
ation was reduced in accordance with the decline in telomerase activity.
Our next aim is to see if rhIL-3 affects the structure of human mast cells.
As shown in Figure 2, the appearance of granules observed by electron micros-
copy looked different between IL-3 (+) and IL-3 (−) cells. It is therefore antici-
pated that the granule content as well as function was different in each cell.
Although tryptase mRNA transcript was reduced at 4 weeks of culture in the
presence of IL-3, no typical differences in tryptase and chymase protein and
mRNA levels were observed at 12 weeks of culture. Surface antigen expres-
sion of CD123, CD18, CD51, CD54, and FcεRIα were also not affected by IL-3.
CD123 was expressed on 4-week-old cultured human cord blood mast cells in
the presence of rhSCF, but 9-week-old cord blood mast cells which showed
substantial expression of β3 integrin became CD123-negative. CD123 was
expressed on isolated human intestinal mast cells (Gebhardt, 2002), but not
on those cells isolated either from lung (Valent, 1990), tonsils (Fureder, 1997),
or kidney (Beil, 1998). As shown in Figure 5, HBMMC did not express CD123
when evaluated by FACS. It is therefore hypothesized that mast cell progeni-
tors proliferate in response to IL-3 via CD123, and become less responsive to
IL-3 as cells proliferate into CD123 (−) mature mast cells.
Histamine release by crosslink of FcεRIα is not significantly different
between the IL-3 (+) and IL-3 (−) groups. However, spontaneous histamine
release mediated by exogenous rhSCF was greater in the IL-3 (−) than in the
IL-3 (+) group. It is reported that IL-6 enhances spontaneous release of hista-
mine from human peripheral blood-derived cultured mast cells from approxi-
mately 2 to 10–15% (Kikuchi, 2002). Although IL-6 was not present in the
histamine release assay, membrane-bound IL-6 during culture might affect
histamine release. The distinct mechanism for the reduction of histamine
release by IL-3 remains to be elucidated.
Finally, GeneChip analysis was performed to see the differences in
unknown transcripts. However, no specific genes were detected to show theEffect of IL-3 on Mast Cell Differentiation 15
difference between IL-3 (+) and IL-3 (−) cells in inactivated and activated with
IgE crosslink. The addition of a low concentration of IL-3 at the early stage of
differentiation was commonly employed to obtain a large number of cultured
mast cells. Our concern was whether IL-3 modulates the structure and func-
tion of mast cell during culture. These data suggest that mast cell structure
and function was not altered by initial activation with IL-3.
In conclusion, IL-3 does not affect the differentiation of human bone
marrow mast cells cultured in the presence of SCF and IL-6. IL-3 was recently
used and recommended to obtain a large number of cord blood mast cells.
Although not increased in human bone marrow system, HBMMC cultured
initially with IL-3 are a good tool for studying mast cell biology. Further
examination is required for additional findings on the modulation of differen-
tiation and function such as spontaneous histamine release.
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